H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on UroGen Pharma (URGN) to $45 from $40 and keeps a Buy rating on the shares. The firm views the company’s Q1 report as solid, saying the commercial launch of Zusduri continues to accelerate.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma Earnings Call Highlights ZUSDURI Surge
- UroGen Pharma price target raised to $40 from $34 at Oppenheimer
- UroGen Pharma reports Q1 EPS (47c), consensus (36c)
- Bancroft Maintains Buy on Zusduri as Commercial Momentum Builds and $35 Price Target Remains Unchanged
- UroGen Pharma: Undervalued Chemoablative Disruptor in NMIBC With Blockbuster Potential by 2030